-
Company Profile
Angion Biomedica Corp – Company Profile
Elicio Therapeutics Inc (Elicio Therapeutics), formerly Angion Biomedica Corp, is a biopharmaceutical company that discovers, develops and commercializes novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The company’s pipeline products include ANG-3070 which treats fibrotic diseases in the kidney and lung; rock2 inhibitor which treats chronic kidney disease and cyp11b2 inhibitor which reduces aldosterone production. It also conducts preclinical development programs in chronic kidney disease including diabetic nephropathy and polycystic kidney disease. The company has offices across...
Add to Basket -
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....
-
Product Insights
Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet,...
-
Product Insights
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Product Insights
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Idiopathic Pulmonary Fibrosis (IPF) symptoms include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness, and weight loss. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents, and anticoagulants. The IPF pipeline drugs market research report provides an analysis of the IPF drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history...
-
Product Insights
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease – Drugs In Development, 2022, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape. Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs...
-
Product Insights
Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis – Drugs In Development, 2022, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Kidney Disease (Chronic Renal Failure) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue, weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease pipeline drugs market research report provides comprehensive information on the Chronic Renal Failure targeted therapeutics, complete with analysis by indications, stage of...
-
Product Insights
Pancreatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of pancreatitis include upper abdominal pain, nausea, vomiting, tenderness while touching the abdomen, weight loss, and upper abdominal pain. It can be treated using antibiotics and medication. The Pancreatitis pipeline market research report provides comprehensive information on the therapeutics under development for Pancreatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and...
-
Product Insights
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glomerulonephritis is a disease of the kidney, characterized by inflammation of the glomeruli. Some factors that increase the chances of getting glomerulonephritis include a family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure. The Glomerulonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers...